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Objectives This study sought to investigate gender-related differences in patients with atrial fibrillation (AF) in Europe.
Background Gender-related differences may play a significant role in AF.
Methods We analyzed the data of 5,333 patients (42% female) enrolled in the Euro Heart Survey on Atrial Fibrillation.
Results Compared with men, the women were older, had a lower quality of life (QoL), had more comorbidities, more often
had heart failure (HF) with preserved left ventricular systolic function (18% vs. 7%, p 0.001), and less often had HF
with systolic dysfunction (17% vs. 26%, p 0.001). Among patients with typical AF symptoms (56% of women, 49%
of men), there was no gender-related difference in the choice of rate or rhythm control. Among patients with atypical
or no symptoms (44% of women, 51% of men), women less frequently underwent rhythm control (39% vs.
51%, p  0.001) than did men. Women underwent less electrical cardioversion (22% vs. 28%, p  0.001). Pre-
scription of oral anticoagulants was identical (65%) in both genders. One-year outcome was similar except that
women had a higher chance for stroke (odds ratio 1.83 in multivariable regression analysis, p  0.019).
Conclusions Women with AF had more comorbidities, more HF with preserved systolic function, and a lower QoL than men. In the
large group with atypical or no symptoms, women were treated appropriately more conservatively with less rhythm
control than men. Women had a higher chance for stroke. Long-term QoL changes and other morbidities and mortal-
ity were similar. (J Am Coll Cardiol 2007;49:572–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.047l
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Trevious studies have reported significant gender differences
n presentation and treatment of cardiovascular disorders,
ith a more conservative management in women (1,2).
In patients with atrial fibrillation (AF), gender differences
n patient characteristics have been described in several
eports (3–5). However, data regarding differences in treat-
ent and outcome are scarce. An underuse of anticoagu-
rom the *University of Athens, Second Cardiology Department, Attikon University
ospital, Athens, Greece; †Academic Hospital Maastricht, Department of Cardiol-
gy, Maastricht, the Netherlands; ‡University Hospital of Heraklion, Department of
ardiology, Heraklion, Greece; §Vivantes Klinikum am Urban, Department of
ardiology, Berlin, Germany; Hopital Nord, Department of Cardiology, Marseille,
rance; ¶Royal Infirmary, Department of Medical Cardiology, Glasgow, Scotland;
University Hospital Münster, Department of Cardiology and Angiology, Münster,
ermany; and **Onassis Cardiac Surgery Center, First Cardiology Department,
thens, Greece.d
Manuscript received April 7, 2006; revised manuscript received September 29,
006, accepted October 16, 2006.ants in women has been suggested, but reports are not
onsistent (3,6–8). The RACE (RAte Control versus
lectrical cardioversion) study, which compared rhythm
ersus rate control in persistent AF, showed a gender-
elated difference in outcome (5): women with rhythm
ontrol had more cardiovascular morbidity and mortality
ompared with those with rate control, whereas this differ-
nce was not seen in men. Women also had a significantly
ower quality of life (QoL) irrespective of strategy.
We examined gender differences in presentation, treat-
ent, and outcome of patients with AF analyzing the data
f the Euro Heart Survey on Atrial Fibrillation.
ethods
he design and main results of the survey have been
escribed recently (9). Between September 2003 and July
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February 6, 2007:572–7 Gender Differences in AF004, 182 centers from 35 European Society of Cardiology
ESC) countries enrolled 5,333 ambulant or hospitalized
atients who had an electrocardiogram or Holter recording
f AF during the qualifying admission or within the
receding 12 months.
Data were collected on patient characteristics and treat-
ent. A clinical follow-up was performed at 1 year after
ischarge. Both at baseline and at 1-year follow-up, QoL
as measured by the EuroQoL questionnaire, producing a
um score for 5 questions on health status (EQ-5D) and a
core of self-reported health status on a visual analogue scale
EQ-VAS) (10,11).
efinitions. Symptoms typical for AF were considered to
e palpitations and syncope. Dyspnea, chest pain, dizziness,
nd fatigue were classified as “other symptoms” possibly
elated to AF.
Heart failure (HF) was defined as the presence of signs
nd symptoms of either right (elevated central venous
ressure, hepatomegaly, dependent edema) or left (exer-
ional dyspnea, cough, fatigue, orthopnea, paroxysmal noc-
urnal dyspnea, cardiac enlargement, rales, gallop rhythm,
ulmonary venous congestion) ventricular failure or both,
nd the diagnosis should be confirmed by noninvasive or
emodynamic measurements. Heart failure with left ventric-
lar systolic dysfunction was defined as HF with a left
entricular ejection fraction 45% or end-diastolic diameter
55 mm in a recent echocardiographic study (within the
receding year). Heart failure with preserved systolic function
as defined as HF in combination with a left ventricular
jection fraction 45% and end diastolic diameter 55 mm.
or other definitions, we refer to the design paper (9). The
merican College of Cardiology (ACC)/American Heart
ssociation (AHA)/ESC 2001 guidelines were used for
atient classification into the different ACC/AHA/ESC
troke risk categories (12).
tatistical analysis. Categorical variables are reported as
ercentage within gender, and were tested for differences
etween men and women with the chi-square test. Age is
eported as mean  1 SD, and was tested with the indepen-
ent t test. The QoL scores (i.e., [change in] EQ-5D and
Q-VAS) are reported as median with interquartile range, and
ere tested with the Mann-Whitney U test because of a
kewed distribution. Significant differences are indicated in the
ables according to p  0.001, p  0.01, or p  0.05; exact p
alues are reported in the Results section for differences not
eported in the tables. Analyses were performed with the
tatistical software package SPSS (version 12.01, SPSS Inc.,
hicago, Illinois). The large sample size may have caused
ifferences that are statistically but not clinically significant.
herefore, the investigators focused on the findings that they
onsidered clinically significant.
Multivariable stepwise logistic regression was performed
o test the independent association of gender with occur-
ence of stroke and major bleeding during 1-year follow-up,
orrecting for differences in age, associated diseases, comor-
idities, and treatment. Variables were removed stepwise mrom the model when the p value
xceeded 0.10. Variables with a p
alue 0.05 in the final model
ere considered to be significant
ontributors and were kept in the
odel. The net odds ratio (OR)
nd its 95% confidence interval
CI) and p value are reported for
ender regarding both analyses.
esults
f the 5,333 enrolled patients,
,249 were female (42%) (Table
). Women were older, had a
ower QoL, and more frequently
ad hypertension, valvular heart
isease, diabetes, and hyperthy-
oidism. Men more frequently
ad coronary artery disease (CAD)
nd idiopathic (lone) AF.
Approximately one-third of
oth men and women had HF.
owever, the HF type differed
ignificantly: HF with preserved systolic function was far
ore frequent among women, HF with systolic dysfunction
as more common among men. In both genders, HF with
ystolic dysfunction was equally often associated with CAD
both 49%, p  0.976), and HF with preserved systolic
unction was equally often associated with hypertension
both 75%, p  0.929). However, HF with preserved
ystolic function was more often associated with valvular
eart disease in women (27% vs. 10%, p  0.001). Women
ad more comorbidities (including more than 1 associated
isease). Especially the higher prevalence of hypertension
nd valvular heart disease resulted in more women being at
he highest risk for stroke according to the ACC/AHA/
SC 2001 guidelines, and in women more often having
ultiple stroke risk factors (54% vs. 39%, p  0.001). At
nrollment, women were more often symptomatic, mainly
ecause of a higher prevalence of palpitations and dyspnea.
Diagnostic procedures are presented in Table 2. Exercise
esting was less commonly performed in women (14% vs.
5%, p  0.001), and when performed, was less often
ssociated with CAD in women (51% vs. 44%, p  0.023).
ransesophageal echocardiography was less often per-
ormed in women to identify left atrial thrombus (73% vs.
1%, p 0.007), and more often to evaluate (artificial) valve
unction (33% vs. 23%, p  0.004).
Interventions for AF are given in Table 3. Women less
ften underwent electrical cardioversion or catheter ablation
han did men. Other interventions showed no substantial
ifference.
Rhythm versus rate control related to symptoms is shown
n Table 4. The treatment strategy did not differ between
Abbreviations
and Acronyms
ACC  American College
of Cardiology
AF  atrial fibrillation
AHA  American Heart
Association
CAD  coronary artery
disease
EQ-VAS  EuroQoL
Questionnaire–Visual
Analogue Scale
EQ-5D  EuroQoL
Questionnaire–Five-
Dimension Score
ESC  European Society
of Cardiology
HF  heart failure
ICD  implantable
cardioverter-defibrillator
OR  odds ratio
QoL  quality of lifeen and women with typical AF symptoms. In the remain-
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Gender Differences in AF February 6, 2007:572–7ng patients (44% of women and 51% of men) with
ymptoms other than palpitations or syncope or with
Baseline Characteristics
Table 1 Baseline Characteristics
Age (yrs)
Concomitant diseases
Heart failure
Heart failure type
Systolic dysfunction§
Preserved systolic function§
New York Heart Association functional class
I
II
III
IV
Hypertension
Coronary artery disease
Valvular heart disease (mitral stenosis or surgery)
Hyperthyroidism
Chronic obstructive pulmonary disease
Idiopathic AF
More than one concomitant disease¶
Comorbidities
Diabetes mellitus
Stroke
Transient ischemic attack
Other systemic thromboembolism
Renal failure
Prior major bleeding
ACC/AHA/ESC stroke risk categories#
Lowest
Low
High
Highest
AF type
First detected
Paroxysmal
Persistent
Permanent
Symptoms
Currently symptomatic
Palpitations
Syncope
Dyspnea
Chest pain
Dizziness
Fatigue
Previously symptomatic, asymptomatic now
Never symptomatic
Health status
EQ-5D
EQ-VAS
*p  0.001. †p  0.01. ‡p  0.05. §Based on available informat
echocardiography at the time of the survey or within the preceding y
disease, thyroid disease, cardiomyopathy, sick sinus syndrome, or c
summarized at “”. #According to Fuster et al. (19).
ACC  American College of Cardiology; AF  atrial fibrillation; A
Dimension Score; EQ-VAS  EuroQoL Questionnaire–Visual Analoguesymptomatic AF, women were treated less aggressively, cith a significantly lower percentage undergoing rhythm
ontrol and a higher percentage undergoing rate control
Women
n  2,249)
Men
(n  3,084) p Value
70  12 64  13 *
35% 33% NS
48% 79%
*
52% 21%
16% 20%
NS
38% 39%
37% 35%
8% 7%
69% 60% *
30% 36% *
15% 7% *
7% 4% *
11% 15% *
7% 13% *
53% 46% *
21% 16% *
7% 5% ‡
6% 5% ‡
4% 2% *
6% 6% NS
2% 2% NS
3% 9%
*
6% 9%
63% 65%
28% 18%
19% 19%
NS
30% 29%
21% 24%
31% 29%
76% 69% *
54% 47% *
4% 4% NS
35% 28% *
18% 15% †
17% 15% NS
28% 26% NS
14% 16% ‡
10% 15% *
3 (0.59–0.85) 0.85 (0.69–1.00) *
0 (50–75) 70 (60–80) *
5% of women and 60% of men with heart failure who underwent
o heart failure, hypertension, coronary artery disease, valvular heart
obstructive pulmonary disease. ¶Taking into account the diseases
merican Heart Association; EQ-5D  EuroQoL Questionnaire–Five-
SC  European Society of Cardiology; NS  not significant.(
0.7
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February 6, 2007:572–7 Gender Differences in AFDischarge therapy is shown in Table 5. Women were
ore commonly prescribed digitalis. The prescription of
ral anticoagulants did not differ. Also, no significant
ifferences were found in oral anticoagulation prescription
ates among the different stroke risk categories according to
he ACC/AHA/ESC 2001 guidelines and CHADS2 stroke
isk score.
Regarding 1-year outcome, the univariable analysis
ielded the following results. Women had a significantly
igher rate of stroke (2.2% vs. 1.2% in men, p  0.011) and
ajor bleeding (2.2% vs. 1.3%, p  0.028). No significant
ifferences between genders were observed regarding mor-
ality (5.1% in women vs. 5.4% in men, p  0.567) or HF
11.2% vs. 11.4%, p  0.878). The QoL changes from
aseline were minimal and did not differ significantly
etween genders (EQ-5D: 0.00 [0.10 to 0.15] in women
s. 0.00 [0.07 to 0.11] in men, p  0.385; EQ-VAS: 0
5 to 15] vs. 0 [5 to 10], p  0.125). When correcting
or differences in age and stroke risk in multivariable logistic
egression, women still had a higher chance for stroke (OR
.83 [95% CI 1.10 to 3.03], p  0.019). Of note, a prior
troke/transient ischemic attack was the only acknowledged
troke risk factor that was more significantly associated with
ccurrence of stroke than female gender. The higher chance
or major bleeding in women became nonsignificant in
ultivariable analysis (OR 1.28 [95% CI 0.76 to 2.13], p 
.351). The difference in stroke rate was largely attributable
o a higher stroke rate in women who did not receive oral
nticoagulation, who had at least 1 stroke risk factor, and
nterventions Performed/Planned at Enrollment
Table 3 Interventions Performed/Planned at Enrollment
Women
(n  2,249)
Men
(n  3,084) p Value
Electrical cardioversion 22% 28% *
Pharmacological conversion attempt 25% 23% NS
Catheter ablation for AF 3% 6% *
Pacemaker implantation 6% 5% NS
ICD implantation 1% 2% †
AF surgery 1% 1% NS
iagnostic Procedures
Table 2 Diagnostic Procedures
Women
(n  2,249)
Men
(n  3,084) p Value
Echocardiography 85% 86% NS
Transthoracic 84% 85% NS
Transesophageal 12% 14% NS
Thyroid hormone level measurement 50% 44% *
Chest radiograph 82% 81% NS
Holter monitoring 28% 30% NS
Exercise test 14% 25% *
Electrophysiological study 4% 7% *
Event recorder 2% 2% NS
p  0.001.
NS  not significant.atheter ablation for AF includes any ablation for AF treatment. *p  0.001. †p  0.05.
AF  atrial fibrillation; ICD  implantable cardioverter-defibrillator; NS  not significant.
*ho underwent rhythm control (5.0% vs. 1.2%, p  0.006).
hen stratifying to the number of stroke risk factors, this
ifference was only significant when 1 solitary stroke risk
actor was present (6.9% vs. 0.5%, p  0.001). In the latter
roup, of 9 strokes in women, 6 were associated with
ypertension, 2 with HF, and 1 with mitral stenosis,
hereas the only stroke in men was associated with hyper-
ension. In contrast with the rhythm control group, there
as no difference in outcome between men and women
ndergoing rate control.
iscussion
omen with AF had a worse cardiovascular risk profile and
lower QoL than men. They were more symptomatic, had
ore comorbidities, and more often had HF with preserved
ystolic function. Women received less often rhythm control
reatment in Relation to Symptoms
Table 4 Treatment in Relation to Symptoms
Women Men p Value
Typical AF symptoms n  1,261 n  1,507
Rhythm control 69% 72%
Rate control 25% 22% NS
No rate/rhythm control 4% 4%
Other symptoms n  377 n  534
Rhythm control 45% 59%
Rate control 44% 33% *
No rate/rhythm control 6% 6%
No symptoms n  610 n  1,041
Rhythm control 36% 46%
Rate control 49% 39% *
No rate/rhythm control 12% 11%
p  0.001.
AF  atrial fibrillation; NS  not significant.
rug Therapy at Dischargen Patients Discharged Alive
Table 5 Drug Therapy at Dischargein Patients Discharged Alive
Women
(n  2,208)
Men
(n  3,056) p Value
Antithrombotic treatment
Oral anticoagulants 65% 65% NS
Aspirin 28% 31% †
Clopidogrel/ticlopidine 5% 6% NS
Heparin/low-molecular-weight heparin 6% 6% NS
Other antithrombotic medication 2% 2% NS
No antithrombotic medication 8% 9% NS
Antiarrhythmic drugs
Class Ia 0.6% 0.4% NS
Class Ic 9% 10% NS
Beta-blocker‡ 49% 51% NS
Class III 29% 32% †
Amiodarone 23% 26% †
Sotalol 7% 7% NS
Class IV§ 10% 8% †
Digoxin/digitoxin 30% 25% *p  0.01. †p  0.05. ‡Including sotalol. §Diltiazem, verapamil.
NS  not significant.
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Gender Differences in AF February 6, 2007:572–7reatment if they had atypical or no symptoms. The use of
ntithrombotic drugs was similar in both genders, also when
orrecting for the higher prevalence of stroke risk factors in
omen. However, women had a higher risk for stroke, and
ithholding oral anticoagulation from patients at risk
ainly seemed to affect women. In this regard, women
ndergoing rhythm control and women with hypertension
s a solitary stroke risk factor seem to be at high risk for
troke. No substantial changes of QoL over time were seen
n either gender. Our results suggest that female gender
hould be reconsidered as an independent risk factor for
troke. In addition, women may benefit from consistent
nticoagulation as well as tailored HF management.
aseline characteristics and evaluation. Female patients
ere older and more frequently had hypertension, valvular
eart disease, diabetes, and thyroid disease; male patients
ore frequently had CAD and idiopathic AF. In total,
omen had more comorbidities, were more often at the
ighest risk for stroke, and were more often symptomatic
han men. These findings agree with those of previous
eports (3–5). The higher frequency of exercise tests in men
annot be ascribed fully to a higher prevalence of CAD.
pparently, women have a lower chance of undergoing an
xercise test in general, and when they do undergo one, it is
ess often in association with CAD.
eart failure. The overall frequency of HF was similar in
oth genders. However, HF with preserved systolic function
as more frequent among women, HF with systolic dys-
unction was more frequent among men. This is a novel
nding in AF patients, and agrees with previous observa-
ions in the total population of HF patients (13). The higher
revalence of HF with systolic dysfunction in men partly
an be explained by the higher prevalence of CAD, but not
xclusively, because in both genders only half of the HF
ases with systolic dysfunction were associated with CAD.
he higher prevalence of HF with preserved systolic func-
ion in women seems mainly attributable to a higher
revalence of hypertension and valvular heart disease.
hythm and rate control. We found significant treatment
ifferences between genders regarding rhythm or rate con-
rol in relation to symptoms. Approximately half of the
atients had typical AF symptoms (palpitations or syncope).
n these, the proportion of patients assigned to rhythm or
ate control did not differ between genders. In the remain-
ng half of the patients who had either atypical or no AF
ymptoms, treatment was more conservative in women,
ith significantly less rhythm control than in men. Consis-
ently, fewer women underwent electrical cardioversion.
hese findings are also novel in the field of AF treatment
nd corroborate the previous reports on a generally more
onservative management of women. This conservative
pproach may have precluded women from appropriate
herapy, i.e., rhythm control of (atypical) AF symptoms. On
he other hand, in asymptomatic patients, this conservative
pproach might have been beneficial for women, because
otential adverse effects of rhythm control interventions and erugs are avoided. Appropriately withholding rhythm con-
rol might even be more beneficial in women than in men,
ecause we found an excess of strokes among women on
hythm control and because rhythm control in women was
ssociated with worse outcome than rate control in the
ACE study.
ntithrombotic medication. In contrast with earlier stud-
es (3,6), there were no differences in the prescription of
ntithrombotic medication, and also not when correcting
or the higher prevalence of stroke risk factors in women.
his could mirror a better guideline implementation, as also
uggested by the higher rate of anticoagulant prescription in
he present survey (65%) compared with prior reports
6–8).
ender and risk for stroke. In the total population,
omen had a higher chance for stroke than men, but no
urther differences were found regarding 1-year outcomes.
revious investigations on outcomes in men and women
rovided contradictory results (3,5). The higher stroke rate
n women in our survey was mainly observed when with-
olding oral anticoagulation from women undergoing
hythm control and having at least 1 stroke risk factor,
ainly hypertension. Because this difference was not exclu-
ively attributable to a higher prevalence of stroke risk
actors in women, these results might indicate a subgroup of
omen that is at high risk for stroke.
These findings agree with the higher stroke rate among
omen in the Framingham study (14), which led to the
ncorporation of female gender in the Framingham stroke
isk scheme (15). These findings also agree with the results
f the SPAF (Stroke Prevention in Atrial Fibrillation) trials
16) and the ATRIA (AnTicoagulation and Risk factors In
trial fibrillation) study, which showed a higher risk for
F-related thromboembolism in women not receiving oral
nticoagulation (17). Interestingly, in the ATRIA study the
eduction in rates of thromboembolism with anticoagula-
ion was larger in women than in men with similar rates of
ajor bleeding (17). However, female gender is not incor-
orated in the most recent stroke risk classification scheme,
HADS2 (18), and the recently revised ACC/AHA/ESC
uidelines classify female gender into the “less validated or
eaker risk factors” (19). Although the higher stroke rate
id not affect mortality in our survey, we speculate that
emale gender should be reconsidered as an independent
troke risk factor.
tudy limitations. Results from surveys like the present
ne could be influenced by a potential center effect because
limited number of centers, of which a large proportion
ere university related and highly specialized, were re-
ruited among the 35 participating countries. The older age
f women may have affected some of the observed differ-
nces, especially in comorbidities. Obviously, in clinical
ractice these differences should be taken into account. In
ddition, some patients had a first detected episode of AF;
thers had paroxysmal, persistent, or permanent AF. How-
ver, because the patient proportions with these different
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February 6, 2007:572–7 Gender Differences in AFF types were almost identical in both genders, this
eterogeneity should not have affected our main results.
onclusions. Women with AF are older and sicker than
en, with a lower QoL. They also seem to be at a higher
isk of stroke, especially when left unprotected. Although
pplied equally among genders, our data suggest that
ntithrombotic treatment must receive more attention in
omen. The higher prevalence of HF with preserved
ystolic function is intriguing and should trigger special
anagement approaches in women. The generally less
ggressive management in women comes to their advantage
ith far less rhythm control in female AF patients with
bsent or atypical AF symptoms. However, this did not
ranslate to a higher QoL, presumably because of higher age
nd higher disease burden.
eprint requests and correspondence: Dr. Nikolaos Dagres,
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